ResearcherUniversity of IowaNo recent work listed
James J. Mezhir
Matched on OpenAlex author ID A5048793026. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 1, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 20
2013: 1 paper · 2014: 1 paper · 2015: 3 papers · 2016: none · 2017: none · 2018: none · 2019: 1 paper
Papers 6
- Nicotinamide phosphoribosyltransferase expression and clinical outcome of resected stage I/II pancreatic ductal adenocarcinoma. Co-author DOI 10.1371/journal.pone.0213576↗
- Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Last author DOI 10.1097/sla.0000000000000796↗
- Pharmacological Ascorbate Radiosensitizes Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-14-1707↗
- Loss of SOD3 (EcSOD) Expression Promotes an Aggressive Phenotype in Human Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-14-1959↗
- An interactive Bayesian model for prediction of lymph node ratio and survival in pancreatic cancer patients. First author DOI 10.1136/amiajnl-2013-002171↗
- RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Adenocarcinoma Patients. Co-author DOI 10.1177/1947601913501074↗
Closest collaborators
The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- B. J. Smith · 2 shared papers, 2013–2014 · strength 0.12
- Paper An interactive Bayesian model for prediction of lymph node ratio and survival in pancreatic cancer patients. DOI 10.1136/amiajnl-2013-002171↗
- Paper RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Ad… DOI 10.1177/1947601913501074↗
- Katelynn E Davis · 1 shared paper, 2019 · strength 0.10
- Carlos H.F. Chan · 1 shared paper, 2019 · strength 0.10
- Bradley D. McDowell · 2 shared papers, 2013–2015 · strength 0.09
- Paper Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. DOI 10.1097/sla.0000000000000796↗
- Paper RABL6A Promotes Oxaliplatin Resistance in Tumor Cells and Is a New Marker of Survival for Resected Pancreatic Ductal Ad… DOI 10.1177/1947601913501074↗
- Douglas Robert Spitz · 2 shared papers, 2015 · strength 0.08
- Bryan G. Allen · 2 shared papers, 2015 · strength 0.08
- Garry R. Buettner · 2 shared papers, 2015 · strength 0.08
- Jessemae L. Welsh · 1 shared paper, 2015 · strength 0.04
- Prabhat C. Goswami · 1 shared paper, 2015 · strength 0.04
- John A. Cieslak · 1 shared paper, 2015 · strength 0.04
- Juan Du · 1 shared paper, 2015 · strength 0.04
- Zita A. Sibenaller · 1 shared paper, 2015 · strength 0.04
- Susan Tsai · 1 shared paper, 2015 · strength 0.04
- Joseph J. Cullen · 1 shared paper, 2015 · strength 0.04
- Wendy Cozen · 1 shared paper, 2015 · strength 0.04
- Charles F. Lynch · 1 shared paper, 2015 · strength 0.04
- Brianne R. O’Leary · 1 shared paper, 2015 · strength 0.04
- Dawn E Quelle · 1 shared paper, 2013 · strength 0.03
- Viviane Palhares Muniz · 1 shared paper, 2013 · strength 0.03
- Xuefeng Zhang · 1 shared paper, 2013 · strength 0.03
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.